2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual
Technical Conferences
Merck Corporate Needs
NanoInk Symposium
Nano Electronics & Photonics
Nano Fabrication
MEMS & NEMS
Sensors & Systems
Micro & Nano Fluidics
MSM - Modeling Microsystems
WCM - Compact Modeling
Nanostructured Materials & Devices
Soft Nanotechnologies & Applications
Nanoparticles in Soft Materials - Colloidal Systems
Polymer Nanotechnology
Carbon Nano Structures & Devices
Nano Particles & Applications
Composites
Nanostructured Surfaces and Interfaces
Nanoscale Characterization
Energy Technologies & Applications
Nanotech in Health, Environment & Society
ICCN - Nanoscale Modeling
Nanoreliability
Bio Nano Materials & Tissues
Bio Sensors & Diagnostics
Biomarkers & Nanoparticles
Cancer Diagnostics, Imaging & Treatment
Drug Delivery & Therapeutics
Nano Medicine
Nanotech to Neurology
Phage Nanobiotechnology
Clean Technology 2008
Industrial Impact Workshop
Confirmed Speakers
Program Committee
Reviewers

Partnering Events:

TechConnect Summit
Clean Technology 2008

Targeted Drug-carrying Filamentous Phage Nanomedicines

Itai Benhar

Itai Benhar

Associate Professor
Tel-Aviv University, Israel

Itai Benhar—Associate Professor at Tel-Aviv University, Israel received in 1992 a PhD in Molecular Biology from the Hebrew University, Hadassah Medical School Jerusalem, Israel, where he studied control of bacterial gene expression. Dr. Benhar did his post doctoral fellowship at the National Cancer Institute, NIH, working with Dr. Ira Pastan on recombinant immunotoxins.

In 1995, Dr. Benhar joined the Department of Molecular Microbiology and Biotechnology of the George S. Wise Faculty of Life Sciences as a tenure-track assistant professor. Dr. Benhar received tenure at 2002, and became an associate professor in 2005. In 2007 Dr. Benhar was appointed as Department Chairman.

Dr. Benhar’s main field of expertise is antibody engineering, and over the years he prepared several phage display libraries from which antibodies against numerous targets were isolated. Research in Dr. Benhar’s group if currently focused on three major topics: 1) evaluation of novel formats of antibody-toxin fusion proteins as potential anti-cancer agents. 2) Evaluation of death switches that are activated by viral proteases for potential eradication of virus-infected cells. 3) Application of filamentous phages as targeted drug-carrying nanomedicines. Research in Dr. Benhar’s lab has been currently funded with grants from the Israeli Health ministry, the Israel Cancer Association and the Israel Science Foundation.

Speaking in the special symposium on Phage Nanobiotechnology.


View Confimed Speakers

← Back to Conferences & Symposia